 |
67 Companies | 59 Products |
|
|
59 Products | |
344 Diseases | |
343 Trials |  |
12261 News |  |
| «12...170171172173174175176177178179180...229230» |
- GSK2636771 / GSK, Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] Safety results from phase I/II study of the PI3Kβ inhibitor GSK2636771 (G) in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5689;
P1/2
Renal toxicity precluded higher doses. No objective responses have been observed although 2 pts have experienced prolonged clinical benefit including a MM pt with 27% decrease in tumor burden.
- Rozlytrek (entrectinib) / Roche, Vitrakvi (larotrectinib) / Bayer, Eli Lilly
[VIRTUAL] Bimodal ntrk expression and correlation with activation of PI3K/AKT pathway in lung cancer. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5478;
Furthermore, high expression in NTRK2 correlates with activation in the PI3K/AKT pathway. This data suggests that therapy targeting NTRK2 overexpression and/or activation of PI3K/AKT pathway in patients with high NTRK2 mRNA should be explored.
- [VIRTUAL] Patho-genomic feature of PI3K / AKT / mTOR pathway mutations in Chinese patients with non-small cell lung cancer. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5374;
As more small molecule inhibitors developed to target PI3K/AKT/mTOR pathway, this study might shed light on further clinical investigation of these lately developed therapeutic approaches. Research Funding: None
- Imbruvica (ibrutinib) / AbbVie, J&J
[VIRTUAL] Correlation of PI3K upregulation with NOTCH2 mutations in ibrutinib-resistant mantle cell lymphoma. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5229;
We identified a strong correlation between gain-of-function NOTCH2 mutations and enriched PI3K signaling, suggesting that dual inhibition of NOTCH and PI3K may overcome ibrutinib resistance in MCL. Research Funding: None
- LX-086 / Luoxin Pharma
[VIRTUAL] Preclinical evaluation of LX-086, a small molecule as a selective inhibitor of PI3K. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3810;
Preclinical studies show antitumor efficacy of LX-086 in PIK3CA mutant and amplified solid cancer models. LX-086 represents a promising clinical candidate for the treatment of solid cancers with PIK3CA mutation or amplification.
- Zarnestra (tipifarnib) / Kura Oncology
[VIRTUAL] Antitumor activity of tipifarnib and PI3K pathway inhibitors in HRAS-associated HNSCC. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3806;
P2
Additional biomarkers associated with sensitivity or resistance and alterations in gene expression (by RNAseq) and oncogenic signaling following treatment either as a monotherapy or in combinations will also be described. Research Funding: Kura Oncology
- fimepinostat (CUDC-907) / Curis, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
[VIRTUAL] Correlation of MYC gene signature variations with clinical response to fimepinostat in patients with aggressive B-cell lymphoma. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3802;
P1
F is currently undergoing active clinical study in combination with venetoclax for the treatment of R/R DLBCL or high grade B-cell lymphoma (HGBL): NCT01742988. Research Funding: Curis, Inc.
- CYH33 / HaiHe Pharma
[VIRTUAL] A first-in-human phase I study of CYH33, a phosphatidylinositol 3-kinase (PI3K) α selective inhibitor, in patients with advanced solid tumors. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3793;
P1
CYH33 single agent and in combination with other anti-tumor agents have be planned in future studies. Research Funding: Shanghai HaiHe Pharmaceutical Co.,Ltd
- Piqray (alpelisib) / Novartis
[VIRTUAL] Use of alpelisib in the treatment of hormone receptor positive metastatic breast cancer: An institutional experience. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3591;
Alpelisib and Fulvestrant could be an effective therapy in patients who have also progressed on systemic chemotherapy including CDK 4/6 inhibitors. Although our sample size is small, we hope that our experience could guide clinicians in the management of patients with HR+ MBC who harbor the PIK3CA mutation and are being treated with Alpelisib.
- paclitaxel / Generic mfg.
[VIRTUAL] Incidence of mutated DNA damage response pathway and clinically actionable alterations in Chinese patients with unknown primary tumor revealed by comprehensive genomic profiling. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_2996;
TMB of CUP patients with altered HRR pathway is significantly higher than ones with intact HRR. Comprehensive genomic profiling revealed the potentiality of target therapy in CUP patients with clinically actionable mutations.
- Piqray (alpelisib) / Novartis, taselisib (GDC-0032) / Roche, IPI-549 / Infinity Pharma
[VIRTUAL] Test measuring signaling activity in live patient tumor cells to identify PI3KCA WT patients who may benefit from PI3K inhibitors. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_2862;
Abnormal pan-PI3K signaling and normal PI3K-α signaling in the HCC1954 cell line correlated with xenograft results. This study thus suggests that measurement of PI3K-involvement in hyperactive S1P signaling in live patient breast cancer cells may provide a means to identify breast cancer patients who may or may not benefit from treatment with PI3K inhibitors.
- gedatolisib (PF-05212384) / Curie Institute, Pfizer
[VIRTUAL] Phase II study of gedatolisib for small-cell lung cancer (SCLC) patients (pts) with genetic alterations in PI3K/AKT/mTOR pathway based on a large-scale nationwide genomic screening network in Japan (EAGLE-PAT/LC-SCRUM-Japan). (Poster Board 257) - Apr 29, 2020 - Abstract #ASCO2020ASCO_2333;
This phase II study didn’t show promising clinical benefit of gedatolisib for advanced SCLC pts with genetic alterations in the PI3K/AKT/mTOR pathway. The safety profile of gedatolisib was similar to that reported previously.
- buparlisib (BKM120) / Novartis, Adlai Nortye
[VIRTUAL] Safety and efficacy of TQ-B3525, a novel and selective oral PI3K α/δ inhibitor, in Chinese patients with advanced malignancies: A phase I dose-escalation and expansion trial. (Poster Board 391) - Apr 29, 2020 - Abstract #ASCO2020ASCO_2178;
P1
Recommended phase II dose was established at 20mg qd. A single-arm phase 2 trial of TQ-B3525 in patients with R/R FL is currently underway.
- Venclexta (venetoclax) / Roche, AbbVie, fimepinostat (CUDC-907) / Curis
[VIRTUAL] Phase Ib trial combining rapid determination of drug-drug interaction (DDI) followed by a dose finding period to assess safety and preliminary efficacy of fimepinostat plus venetoclax in patients with aggressive B-cell lymphoma. (Poster Board 389) - Apr 29, 2020 - Abstract #ASCO2020ASCO_2176;
P1
Enrollment in Cohort 2 remains on-going. Research Funding: Curis, Inc.
- [VIRTUAL] Reassessing PI3K Inhibitors in Indolent Lymphomas () - Apr 29, 2020 - Abstract #ASCO2020ASCO_2136;
- [VIRTUAL] Results of a completed phase I study of LAM-002 (apilimod dimesylate), a first-in-class phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) inhibitor, administered as monotherapy or with rituximab or atezolizumab to patients with previously treated follicular lymphoma or other B-cell cancers. (Poster Board 350) - Apr 29, 2020 - Abstract #ASCO2020ASCO_2135;
P1
LAM-002 does not cause the myelosuppressive or immune adverse events associated with lenalidomide or PI3K inhibitors. Promising efficacy supports registration-directed Phase 2/3 testing of LAM-002 monotherapy and combination therapy for patients with previously treated follicular lymphoma.
- Afinitor (everolimus) / Novartis
[VIRTUAL] Detection of actionable gene mutations in breast cancer by amplicon-based next-generation sequencing liquid biopsy. (Poster Board 120) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1761;
Importantly, other driver mutations were also observed at similar frequencies as external tissue studies, implying high sensitivity as the primary reason for performance. This supports the clinical utility of an amplicon-based NGS-based approach to liquid biopsy for the sensitive detection of actionable mutations in breast cancer.
- [VIRTUAL] Incidence of PI3K pathway alteration and response to neoadjuvant therapy (NAT) in triple negative breast cancer (TNBC) subtypes. (Poster Board 53) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1678;
P=N/A
The incidence of PI3K pathway alteration varied by TNBC subtype but was not associated with pathologic response to NAT with the exception of increased substantial residual disease (RCB II-III) in the M subtype. Research Funding: MD Anderson MoonShot, Conquer Cancer Foundation of the American Society of Clinical Oncology
- [VIRTUAL] Comprehensive molecular analysis of microsatellite-stable (MSS) tumors with high mutational burden in gastrointestinal (GI) cancers. (Poster Board 361) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1580;
This is the largest study to investigate the special molecular landscape of pts with TMB-H & MSS in GI cancers. Our data may provide novel insights for pt selection and more effective targeted combination immunotherapies (e.g. HER2, PI3K inhibitors) in GI cancers.
- [VIRTUAL] Therapeutic vulnerabilities among KRAS G12C mutant (mut) advanced cancers based on co-alteration (co-alt) patterns. (Poster Board 355) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1574;
The co-alt patterns highlight relevant oncogenic pathways and candidate drugs for future combination therapies. Co-inhibition of PI3K-mTOR and MAPK pathways has shown synergism in prior pre-clinical studies but had poor tolerance in pts.
- [VIRTUAL] Targeting Upstream and Downstream Effectors in the PI3K Signaling Cascade () - Apr 29, 2020 - Abstract #ASCO2020ASCO_1456;
- Aliqopa (copanlisib) / Bayer
[VIRTUAL] Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_1454;
P2
Further study either alone or in combinations in select tumors is warranted. G3/4 toxicities observed were consistent with reported toxicities for PI3K pathway inhibition.
- | Preclinical, Journal: SRPK1 gene silencing promotes vascular smooth muscle cell proliferation and vascular remodeling via inhibition of the PI3K/Akt signaling pathway in a rat model of intracranial aneurysms. (Pubmed Central) - Apr 29, 2020
Our results show that siRNA-mediated silencing of SRPK1 gene inhibits VSMC apoptosis, and increases VSMCs proliferation and vascular remodeling in IA via the PI3 K/Akt signaling pathway. Our findings provide a novel intervention target for the molecular treatment of IA.
- | Journal: Sclerosing Epithelioid Fibrosarcoma of the Bone With Rare EWSR1-CREB3L3 Translocation Driving Upregulation of the PI3K/mTOR Signaling Pathway. (Pubmed Central) - Apr 29, 2020
Open-ended RNA-based fusion gene testing coupled with MUC4 immunohistochemistry aided the eventual diagnosis in this case. Herein, we report the third case of SEF with EWSR1-CREB3L3 translocation and show that this fusion leads to aberrant upregulation of the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway in heterologous cell models.
- | Journal: Towards Enhancing Therapeutic Glycoprotein Bioproduction: Interventions in the PI3K/AKT/mTOR Pathway (Pubmed Central) - Apr 29, 2020
The PI3K/Akt/mTOR signaling pathway is a key regulator of diverse physiological functions such as proliferation, global protein, and lipid synthesis as well as many metabolic pathways interacting to increase secretory capabilities. In this review we detail various strategies previously employed to increase glycoprotein production yields via either genetic or pharmacological over-activation of the PI3K/Akt/mTOR pathway, and we discuss their potential and limitations.Key words: mTORC1, CRISPR, specific productivity, translation.
- || Koselugo (selumetinib) / Merck (MSD), AstraZeneca, docetaxel / Generic mfg.
Biomarker, Clinical, Journal: Defining subpopulations of differential drug response to reveal novel target populations. (Pubmed Central) - Apr 28, 2020
A systematic analysis of preclinical data for a failed phase III trial of selumetinib combined with docetaxel in lung cancer suggests potential indications in pancreatic and colorectal cancers with KRAS mutation. This data-informed study exemplifies a method for stratified medicine to identify novel cancer subpopulations, their genetic biomarkers, and effective drug combinations.
- | Journal, IO Biomarker: Naringin inhibits thyroid cancer cell proliferation and induces cell apoptosis through repressing PI3K/AKT pathway. (Pubmed Central) - Apr 28, 2020
In conclusion, the data of this study suggested that naringin presented anti-tumor effects in TC cells through inhibiting TC cell proliferation and inducing cell apoptosis via regulating the expression of cell proliferation and apoptosis related genes and PI3K/AKT pathway activation. Our study suggested the potential value of naringin in the treatment of TC and provided more theoretical evidence for the treatment of TC.
- | Journal: MicroRNA-129-5p suppresses proliferation, migration and invasion of retinoblastoma cells through PI3K/AKT signaling pathway by targeting PAX6. (Pubmed Central) - Apr 28, 2020
Our study suggested the potential value of naringin in the treatment of TC and provided more theoretical evidence for the treatment of TC. This study provides evidences that RB progression was suppressed by overexpressed miR-129-5p via direct targeting of PAX6 through PI3K/AKT signaling pathway, which may provide a molecular basis for better treatment for RB.
- | tamoxifen / Generic mfg.
Journal: PI3K/AKT Signaling in Breast Cancer Molecular Subtyping and Lymph Node Involvement. (Pubmed Central) - Apr 28, 2020
The same AKT3 resulted to be a possible candidate predictive biomarker for Tamoxifen response. In conclusion, our study highlighted the complex regulation of the PI3K/AKT pathway in BC and its differences in BC patients with and without lymph node involvement.
- | Journal: Correction: Thrombin induces ICAM-1 expression in human lung epithelial cells via c-Src/PDGFR/PI3K/Akt-dependent NF-κB/p300 activation. (Pubmed Central) - Apr 28, 2020
In conclusion, our study highlighted the complex regulation of the PI3K/AKT pathway in BC and its differences in BC patients with and without lymph node involvement. No abstract available
- | buparlisib (AN2025) / Adlai Nortye
Trial completion date, Trial primary completion date, Metastases: Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium (clinicaltrials.gov) - Apr 27, 2020
P2, N=35, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
No abstract available Trial completion date: Mar 2020 --> Mar 2021 | Trial primary completion date: Mar 2020 --> Mar 2021
- | Byetta (exenatide) / AstraZeneca
Preclinical, Journal: Exendin-4 attenuates brain mitochondrial toxicity through PI3K/Akt-dependent pathway in amyloid beta (1-42)-induced cognitive deficit rats. (Pubmed Central) - Apr 26, 2020
Thus, it can be speculated that Exendin-4 may mitigate AD-like manifestations including mitochondrial toxicity perhaps through PI3K/Akt-mediated pathway in the experimental animals. Hence, Exendin-4 could be a potential therapeutic alternative candidate in the management of AD.
- | sirolimus / Generic mfg., University of Cincinnati
Journal: Emodin-induced autophagy against cell apoptosis through the PI3K/AKT/mTOR pathway in human hepatocytes. (Pubmed Central) - Apr 26, 2020
In conclusion, emodin exhibited cytotoxicity in the L02 human hepatic cell line by promoting apoptosis, and it also induced autophagy through the suppression of the PI3K/AKT/mTOR signalling pathway. The autophagy could play a protective role following emodin treatment.
- | cisplatin / Generic mfg.
Journal: Platycodon grandiflorus enhances the effect of DDP against lung cancer by down regulating PI3K/Akt signaling pathway. (Pubmed Central) - Apr 26, 2020
Cisplatin (DDP) is a first-line drug for non-small cell lung cancer (NSCLC), but its efficacy and applications are constrained by intolerance and serious side effects...Therefore, vitro studies showed that PG combined with DDP down-regulated the expression of p-Akt and PI3K and improved the protein expression of cleaved-caspase 9 in A549 cell and PG promotes the apoptosis of DDP and these mechanisms were related by inhibition of the PI3K/Akt signaling pathway. Our study confirms that the combination of PG and DDP will help enhance efficacy of DDP and is important for improving platinum-based chemotherapy.
- | Preclinical, Journal: Scutellarin suppresses cartilage destruction in osteoarthritis mouse model by inhibiting the NF-κB and PI3K/AKT signaling pathways. (Pubmed Central) - Apr 26, 2020
Furthermore, the cellular mechanism underlying the protective effect of scutellarin in OA was clearly associated with the NF-κB and PI3K/AKT signaling pathways. Collectively, this study proposes scutellarin as a potential therapeutic to treat joint degenerative diseases, including OA.
- | Journal: Oroxin B Induces Apoptosis by Down-Regulating MicroRNA-221 Resulting in the Inactivation of the PTEN/PI3K/AKT Pathway in Liver Cancer. (Pubmed Central) - Apr 26, 2020
Therefore, OB effectively exerts anticancer effects by positively regulating the PTEN gene and then inactivating the PI3K/Akt signaling pathway through down-regulating the expression of the microRNA-221, thereby inducing apoptosis of liver cancer cells. This study offers a theoretical evidence for further development and clinical guidance of OB as an anti-tumor agent.
- | quercetin (LY294002) / Eli Lilly
Preclinical, Journal: p75NTR mice exhibit an alveolar bone loss phenotype and inhibited PI3K/Akt/β-catenin pathway. (Pubmed Central) - Apr 26, 2020
Deletion of p75NTR reduced alveolar bone mass in mice. P75NTR positively regulated the osteogenic differentiation of EMSCs via enhancing the PI3K/Akt/β-catenin pathway.
- | Preclinical, Journal: [Corrigendum] Cortex Mori Radicis Extract promotes neurite outgrowth of diabetic rats by activating PI3K/AKT signaling and inhibiting Ca2+ influx associated with upregulation of transient receptor potential canonical channel 1. (Pubmed Central) - Apr 25, 2020
The authors are grateful to the Editor for allowing them the opportunity to publish this Corrigendum, and wish to apologize to the readership of the Journal for any inconvenience caused. [the original article was published in Molecular Medicine Reports 21: 320‑328, 2020; DOI: 10.3892/mmr.2019.10839].
- | cisplatin / Generic mfg.
Journal: LncRNA UCA1 promotes cisplatin resistance in gastric cancer via recruiting EZH2 and activating PI3K/AKT pathway. (Pubmed Central) - Apr 25, 2020
Hence, UCA1 promotes cisplatin resistance of GC via recruiting EZH2 and activating PI3K/AKT pathway. Our research revealed the lncRNA UCA1 promoted the cisplatin resistance of GC by recruiting EZH2 and activating PI3K/AKT pathway to modulate cell apoptosis, indicating treatments targeting UCA1 or EZH2 might provide meaningful therapeutic strategies for cisplatin-resistance GC patients.
- The Inhibition of Phosphatidylinositol-3-Kinase in activated T-cells by Hibiscone C derivatives (Board Number: P798) - Apr 25, 2020 - Abstract #IMMUNOLOGY2020IMMUNOLOGY_2332;
Via analysis of phosphorylation of the downstream effector molecule Akt in activated T cells, we demonstrate that Hibiscone C also can irreversibly inhibit PI3K activity, however not as effectively as wortmannin. These results led us to test other derivatives of hibiscone C, to see if modifications to the molecule’s structure would affect potency of the molecule.
- A novel role for TRIM6 and unanchored ubiquitin in inflammatory disease during virus infection via the PI3K-AKT signaling pathway (Board Number: P501) - Apr 25, 2020 - Abstract #IMMUNOLOGY2020IMMUNOLOGY_2172;
Mechanistically, TRIM6 and unanchored Ub form a complex with PI3K-AKT signaling components and their phosphorylation is impaired in Trim6-/- cells leading to reduced CXCL1 expression. Our study uncovers a novel mechanism by which viruses can cause disease and suggest that inhibition of CXCL1 signaling may be used as a therapeutic strategy to highly pathogenic viruses.
- Arginase-1 production by myeloid cells in tumor microenvironment induce inflammasome activation and activate PI3K pathway in tumor-associated macrophages in head and neck cancer (Board Number: P1141) - Apr 25, 2020 - Abstract #IMMUNOLOGY2020IMMUNOLOGY_693;
These results indicate a mechanistic role of TAMs and Arginase-1 containing exosomes in the tumor microenvironment by activation of autophagy and inflammasome, and induction of the EMT. The mechanistic links presented in this study regarding the role of arginase in head and neck cancer pathogenesis could be targeted as therapeutic strategies.
- PI3K-dependent Reprogramming of Hexokinase Isoforms Regulates B Lymphocyte Metabolism (Board Number: P716) - Apr 25, 2020 - Abstract #IMMUNOLOGY2020IMMUNOLOGY_370;
Taken together, our study reveals that PI3K-dependant reprogramming of hexokinase isoforms can impact on B cell glycolysis and other metabolic pathways. Studies in progress are examining the functional importance of HK2 in antibody responses using mice with B cell-specific deletion of this enzyme.
- | quercetin (LY294002) / Eli Lilly
Journal: TRIM59 attenuates inflammation and apoptosis caused by myocardial ischemia reperfusion injury by activating the PI3K/Akt signaling pathway. (Pubmed Central) - Apr 25, 2020
Studies in progress are examining the functional importance of HK2 in antibody responses using mice with B cell-specific deletion of this enzyme. TRIM59 reduces the level of inflammation and apoptosis of myocardial cells caused by MIRI by activating the PI3K/Akt signaling pathway, thereby reducing myocardial injury.
- || BGT226 / Novartis
Biomarker, Clinical, P1 data, Journal: Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers. (Pubmed Central) - Apr 24, 2020
Treatment with BGT226 did not change any of the biomarkers in neither normal skin nor tumor tissues. BGT226 was tolerated up to 100 mg three times a week in Japanese patients with solid cancers, without difference in toxicity profiles and pharmacokinetics compared to Western patients.
- || Biomarker, Clinical, Journal: Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors. (Pubmed Central) - Apr 24, 2020
BGT226 was tolerated up to 100 mg three times a week in Japanese patients with solid cancers, without difference in toxicity profiles and pharmacokinetics compared to Western patients. Previous steroid use and lower baseline HbA1c level may be important predictors for developing diabetes in patients with advanced solid tumors treated with PI3K inhibitors, warranting close observation and careful intervention.
- | Preclinical, Journal: Targeting c-MYC through Interference with NAMPT and SIRT1 and Their Association to Oncogenic Drivers in Murine Serrated Intestinal Tumorigenesis. (Pubmed Central) - Apr 23, 2020
Targeting the feedback loop exerted a unique, dual therapeutic effect of oncoprotein inhibition and tumor suppressor activation. It may therefore represent a promissing target for serrated colorectal cancer, and presumably for other cancer types with deregulated c-MYC.
- | chloroquine phosphate / Generic mfg., quercetin (LY294002) / Eli Lilly
Preclinical, Journal: Dexmedetomidine prevents septic myocardial dysfunction in rats via activation of α7nAChR and PI3K/Akt- mediated autophagy. (Pubmed Central) - Apr 23, 2020
For the first time, these data indicate that autophagy is central in Dex-mediated cardio-protection in sepsis. These observations provide the foundation for further study, and may serve as the basis for innovative therapeutic strategies against septic myocardial dysfunction.
- | Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
Journal: The evolving treatment landscape of chronic lymphocytic leukemia. (Pubmed Central) - Apr 23, 2020
A deep knowledge of currently available evidences is key to tailor treatment choice and optimize long-term tolerability and disease control. Fixed-duration combinations are investigated to allow treatment holidays and avoid the emergence of resistant clones under the selective pressure of continuous treatment.
- | Journal: Kochia scoparia seed extract suppresses VEGF-induced angiogenesis via modulating VEGF receptor 2 and PI3K/AKT/mTOR pathways. (Pubmed Central) - Apr 23, 2020
3-OH-tyrosol (1.63 mg/g) and morin hydrate (0.17 mg/g) were identified in KSE. KSE inhibits angiogenesis in HUVECs as well as proliferation in human prostate cancer cells, suggesting KSE may be useful herbal medicine for preventing progression of prostate cancer and angiogenesis.